Related Experiment Video

Updated: Aug 30, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

[Tissue plasminogen activator and plasminogen activator inhibitor gene polymorphisms: possible relation to

N D Selezneva1, D A Zateĭshchikov, B A Sidorenko

  • 1Presidential Medical Center of Russia, Central Clinical Hospital, ul. Marshala Timoshenko 15, 121356 Moscow, Russia.

Kardiologiia
|November 1, 2003
PubMed

Insights

Genetic variants in plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator (tPA) genes show potential links to ischemic heart disease and atherosclerosis. More research is needed to confirm their role in pathogenesis and thrombotic complications.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Biology
  • Thrombosis Research

Context:

  • Plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator (tPA) are key regulators of fibrinolysis.
  • Genetic variations in PAI-1 and tPA genes may influence their activity and plasma concentrations.
  • Ischemic heart disease and atherosclerosis are complex conditions with multifactorial etiologies, including genetic predispositions.

Purpose:

  • To review and synthesize current data on the association between PAI-1 and tPA gene polymorphisms and ischemic heart disease (IHD) and atherosclerosis.
  • To explore the influence of these polymorphisms on PAI-1 and tPA synthesis, plasma levels, and their potential role in disease pathogenesis.
  • To evaluate the existing clinical evidence supporting or refuting the connection between these genetic markers and vascular diseases.

Summary:

  • The review summarizes findings on PAI-1 and tPA gene polymorphisms and their association with IHD and atherosclerosis.
  • It discusses the synthesis, regulation, and genetic variations of PAI-1 and tPA, including their impact on protein levels and thrombotic risk.
  • Current evidence is insufficient for a definitive conclusion on the role of these polymorphisms in atherosclerosis pathogenesis, highlighting the need for further studies.

Impact:

  • Identifies knowledge gaps regarding the genetic contribution of PAI-1 and tPA polymorphisms to cardiovascular diseases.
  • Suggests the necessity for large-scale genetic studies in high-risk populations to elucidate the role of these markers.
  • Provides a foundation for future research into personalized medicine approaches for preventing IHD and atherosclerosis based on genetic profiles.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...